ArticlePLoS neglected tropical diseases2025
From neglected to notable: A growing public health challenge driven by hospitalization for sporotrichosis in Pernambuco, Northeast Brazil (2016-2024).
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Localized Cutaneous Versus Deep Sporotrichosis at Hospital das Clínicas, UFMG, Belo Horizonte, Brazil: A Cohort of 213 Culture-Confirmed Cases, 2011 to 2026.Journal of fungi (Basel, Switzerland) · 2026Article
- Antifungal and Therapeutic Evaluation of l- and d‑Enantiomers of a Plant Defensin-Inspired Peptide againstACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opportunistic and endemic mycoses represent a significant global health concern, particularly in Brazil. In the northeastern state of Pernambuco (PE), sporotrichosis has become a rapidly escalating public health challenge, evidenced by a notable increase in hospital admissions, despite its mostly outpatient nature. The present study, therefore, aimed to investigate the epidemiological and clinical profile of mycosis-related hospitalizations in PE from 2016 to 2024, with a primary focus on the burden of sporotrichosis. This statewide surveillance study used data from Brazil's Unified Health System Hospital Information System (SIH/SUS) to conduct a descriptive and comparative assessment of hospitalizations for ten fungal diseases in PE and nationally. Incidence rates and the Error, Trend, Seasonality (ETS) framework were applied to forecast case numbers for 2025. A total of 794 hospitalizations were recorded in PE during the study period. The most prevalent infections were aspergillosis (23.0%), sporotrichosis (17.5%), cryptococcosis (15.1%), and chromoblastomycosis (13.6%), with an overall mortality rate of 10.5%. Hospitalizations for sporotrichosis rose from five cases in 2016-28 in 2021, with local incidence rates surpassing the national average. This implantation mycosis showed a marked concentration in Recife, reflecting the zoonotic spread of Sporothrix brasiliensis in urban areas. Notably, 46.0% of sporotrichosis cases were classified as unspecified, underscoring gaps in reporting. Among specified cases, the lymphocutaneous form predominated (18.7%), followed by disseminated disease (17.3%). Forecasts for 2025 indicate a persistently high hospitalization burden. These findings highlight a pressing public health issue in PE. The surge in sporotrichosis cases and the high share of severe and unspecified forms point to weaknesses in diagnosis and data recording. Tackling this emerging endemic-epidemic threat requires improved surveillance, mandatory notification, and better data capture in SIH/SUS, alongside integrated actions across human, animal, and environmental health sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.